Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial.

ABSTRACT:

Importance

Most patients with locally advanced hepatocellular carcinoma (HCC) recur within the liver following systemic therapy.

Objective

To determine whether stereotactic body radiation therapy (SBRT) improves outcomes in patients with locally advanced HCC compared with sorafenib alone.

Design, setting, and participants

This multicenter phase 3 randomized clinical trial randomized patients with HCC 1:1 to sorafenib or SBRT followed by sorafenib, stratified by performance status, liver function, degree of metastases, and macrovascular invasion. Eligible patients had HCC unsuitable for or refractory to standard local-regional therapies and were candidates for first-line systemic therapy. Data were collected from April 2013 to March 2021, and data were analyzed from Ju

SUBMITTER: Dawson LA 

PROVIDER: S-EPMC11843352 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature